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Abstract: Patients with inflammatory bowel disease (IBD) often present poor bone health and are 40%
more at risk of bone fracture. Studies have implicated autophagy in IBD pathology and drugs used to
treat IBD stimulate autophagy in varying degrees, however, their effect on the skeleton is currently
unknown. Here, we have utilised the dextran sulphate sodium (DSS) model of colitis in mice to
examine the effects of the thiopurine drug azathioprine on the skeleton. Ten-week-old male mice
(n = 6/group) received 3.0% DSS in their drinking water for four days, followed by a 14-day recovery
period. Mice were treated with 10 mg/kg/day azathioprine or vehicle control. Histopathological
analysis of the colon from DSS mice revealed significant increases in scores for inflammation severity,
extent, and crypt damage (p < 0.05). Azathioprine provided partial protection to the colon, as reflected
by a lack of significant difference in crypt damage and tissue regeneration with DSS treatment.
MicroCT of vehicle-treated DSS mice revealed azathioprine treatment had a significant detrimental
effect on the trabecular bone microarchitecture, independent of DSS treatment. Specifically, significant
decreases were observed in bone volume/tissue volume (p < 0.01), and trabecular number (p < 0.05),
with a concurrent significant increase in trabecular pattern factor (p < 0.01). Immunohistochemical
labelling for LC3 revealed azathioprine to induce autophagy in the bone marrow. Together these data
suggest that azathioprine treatment may have a deleterious effect on IBD patients who may already
be at increased risk of osteoporotic bone fractures and thus will inform on future treatment strategies
for patient stratification.
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1. Introduction
Inflammatory bowel disease (IBD) is the name given to a group of conditions that affect the
colon and the small intestine. The two main forms of IBD are ulcerative colitis and Crohn’s disease.
Crohn’s disease can affect any part of the gastrointestinal tract and can cause transmural inflammation.
In contrast, ulcerative colitis causes mucosal inflammation and is limited to the colon [1]. A recent
review by NHS England revealed that the prevalence of IBD was 400 in every 100,000 people, which
results in a total cost of £720 million a year in costs to the NHS [2].
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Osteoporosis has been associated as secondary to a number of gastrointestinal conditions, including
IBD [3,4]. Osteoporosis is a metabolic disease of the bone characterised by a reduction in bone mineral
density and alterations in bone structure, which increases the likelihood of bone fracture. Significantly,
patients with IBD often present with low bone mineral density (BMD), and are 40% more at risk of
bone fracture than healthy individuals [3].
A number of risk factors exist for osteoporosis in IBD patients including malabsorption, chronic
inflammation, low body mass index, use of glucocorticoids, vitamin D deficiency, and surgery [5].
Intestinal absorption of key determinants of bone health (e.g., calcium and vitamin D) is often
compromised in IBD due to the reduction of intestinal mucosa [4]. Indeed, patients with IBD present
with vitamin D [6,7] and calcium deficiencies [8]. IBD is also characterised by the chronic release of
pro-inflammatory cytokines such as IL-6 and tumour necrosis factor-α (TNF-alpha)—the increased
production of these cytokines can stimulate the receptor activator of nuclear κB (RANK)/RANK
ligand (RANKL)/osteoprotegerin (OPG) axis and thus drive osteoclastic bone resorption [9–11].
Low body mass index is a well-established risk factor for low BMD and fracture, and studies have
shown similar associations in patients with IBD [12]. However, other mechanisms may exist and
the development of targeted therapies for bone loss in IBD requires a better understanding of the
underlying cellular mechanisms.
Drugs used to treat IBD include glucocorticoids, immunosuppressants, aminosalicylates (5-ASA),
and biologic agents. Risk of osteoporosis has been shown to be twice as high in IBD patients on
corticosteroids [13], which is thought to be due to their effects on the RANK/RANKL/OPG axis,
sex hormones, and calcium absorption [14]. Conversely, IBD patients on the monoclonal antibody
infliximab have shown increases in their BMD and markers of bone turnover [15–17]. Similarly, patients
on dual anti-TNF-α (infliximab or adalimumab) and azathioprine saw a significant positive effect on
BMD at the lumbar spine [18]. There is an increasing demand to optimise existing medical therapies
through patient stratification and personalised medicine [19]. We and others have previously shown
that drugs currently used for treating IBD can affect the autophagy pathway [20]. Autophagy is an
essential self-eating process that can degrade intracellular components such as organelles, foreign
bodies, and insoluble protein aggregates through the formation and maturation of double membrane
vesicles known as autophagosomes [21]. Specifically, we have shown that the thiopurine drug
azathioprine is a potent inducer of autophagy in the colon, however its effects on bone health have yet
to be established [22].
To directly examine this we have studied bones from a mouse model of IBD using dextran sulphate
sodium (DSS)-induced colitis, which has been extensively used and validated by others to induce acute
and chronic forms of inflammatory bowel disease. This model of colitis in mice is thought to involve
the deterioration of the intestinal epithelial barrier through increased cell apoptosis, therefore allowing
the influx of antigens and microorganisms and the subsequent increased expression of inflammatory
markers [23,24]. Histologically, the colitis induced in this murine model exhibits a wide range of
features similar to that seen in man [23]. Further, we and others have previously shown that DSS
treatment causes detrimental effects on bone trabecular microarchitecture [25,26]. Here we have used
the DSS model to examine the effects of azathioprine treatment on the skeleton in the context of IBD.
The dose and duration of the DSS treatment, and the age, sex, and strain of the mice used were based
on our previous study [26]. Male mice were also used to avoid any confounding actions of oestrogen
on the skeleton. Data from this approach will help inform on personalised therapies for patients with
poor bone health in IBD.
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2. Results
2.1. Effect of Azathioprine on Body Weight in DSS Treated Mice
To assess the effects of azathioprine on body weight of mice, colitis was induced with 3% DSS for
4 days in the presence of azathioprine (DSS/azathioprine) or vehicle control (DSS/vehicle). During
the DSS treatment period (0–4 days), no significant weight loss was observed in any mouse treatment
groups (Figure 1). Independent of azathioprine treatment, mice exhibited a rapid and significant
weight loss from day 4 following DSS treatment (up to 7% in comparison to non-DSS treated mice,
p < 0.05). Following this period of rapid weight loss, DSS/vehicle treated mice proceeded to gain
weight until the end of the study. Weight gain was observed throughout the study period in the
non-DSS/vehicle treated mice (Figure 1). In contrast, DSS/azathioprine treated mice exhibited a rapid
and significant weight loss, followed by a brief period of weight gain, which plateaued from day 10
onwards (Figure 1). Non-DSS/azathioprine treated mice showed no significant weight gain throughout
the experiment (Figure 1). Full details of the weight measurements and statistical significance over the
18-day treatment period is detailed in Supplementary Table S1.
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crypt damage (Figure 2D, p < 0.05) in comparison with the non-DSS/vehicle mice. 
No significant differences were observed in tissue regeneration (Figure 2C) and crypt damage 
(Figure 2D) in non-DSS/azathioprine and DSS/azathioprine treated mice, indicative of a partial 
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examined were also observed, with significant pathology localised to the distal aspect of the colon 
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Figure 1. Body weight changes of azathioprine and vehicle treated mice treated with dextran sulphate
sodium (DSS) followed by a recovery period. Percentage change in body weight of azathioprine
and vehicle mice treated with or without 3% DSS for 4 days. Data are presented as mean ± S.E.M
(n = 6/group).
2.2. Effect of Azathioprine on Colon Pathology in DSS Treated Mice
To assess the effects of DSS on mucosal integrity, detailed histological analysis was performed on
the colon from control and DSS/azathioprine or DSS/vehicle mice. Histological scores for all parameters
were minimal in the non-DSS treated mice, and there were no notable differences observed with
azathioprine treatment in this group (Figure 2). In contrast, histological analysis of the colon from DSS
mice revealed significant increases in scores for inflammation severity (Figure 2A, p < 0.05) and extent
(Figure 2B, p < 0.01), consistent with previous studies and indicative of successful induction of colitis.
It was also observed that the colons from DSS/vehicle mice showed decreased tissue regeneration
(as indicated by the higher regeneration score; Figure 2C, p < 0.05) and increased crypt damage
(Figure 2D, p < 0.05) in comparison with the n -DSS/vehicle mice.
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Data are presented as mean ± S.D. (n = 6/group). * p < 0.05, ** p < 0.01. Scale bar = 100 µm. 
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Figure 2. Colon pathology of azathioprine and vehicle treated mice treated with 3% DSS. Histological
scoring of colons, (A) Inflammation severity score; (B) inflammation extent score; (C) regeneration
score; (D) crypt damage score; (E) representative Hematoxylin & Eosin -stained sections of colon. Data
are presented as mean ± S.D. (n = 6/group). * p < 0.05, ** p < 0.01. Scale bar = 100 µm.
No significant differences were observed in tissue regeneration (Figure 2C) and crypt damage
(Figure 2D) in non-DSS/azathioprine and DSS/azathioprine treated mice, indicative of a partial
protection of azathioprine treatment to the colon. Regional specific chang s in the parameters examined
w re also observed, with significant pathology localised to the distal aspect of the colon (Figure S1).
2.3. Effect of Azathioprine on Bone Phenotype in DSS Treated Mice
DSS-treated mice showed worsened trabecular microarchitecture compared with non-DSS treated
mice as demonstrated by micro computed-tomography (CT) (Figure 3A). Specifically, DSS-treated mice
exhibited a significant decrease in trabecular thickness (Figure 3D, p < 0.05). Non-significant decreases
in bone volume/tissue volume (BV/TV) (Figure 3B), and trabecular number (Figure 3C), and increases
in trabecular separation (Figure 3E) and pattern factor (Figure 3F) were also observed in DSS-treated
mice. Treatment with azathioprine alone had a significant detrimental effect on the trabecular bone
microarchitecture, independent of DSS treatment. Indeed, significant decreases were observed in
BV/TV (Figure 3B, p < 0.01), and trabecular number (Figure 3C, p < 0.01), with a concurrent significant
increase in trabecular pattern factor (Figure 3F, p < 0.05) indicative of a more disorganised trabecular
structure. No effects of DSS or azathioprine treatment were observed on trabecular BMD (Figure 3G).
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treated with azathioprine (Figure 4Aiii,iv, in comparison to Figure 4Ai). To examine whether 
azathioprine affects autophagy activity in the skeleton of mice, immunohistochemistry for the 
autophagy marker LC3 was conducted. LC3 labelling was observed in the osteoblasts lining the 
trabecular bone, in the osteocytes and throughout the bone marrow. No differences were observed 
between non-DSS and DSS treated mice (Figure 4Ci, in comparison to Figure 4Cii). However, 
azathioprine treatment appeared to modestly increase the intensity of LC3 labelling, independent of 
DSS treatment and in particular within the bone marrow, although no significant differences were 
observed upon quantification of immunolabelling intensity (Figure 4Ciii,iv, in comparison with 
Figure 4Ci,ii, Figure S2). 
Figure 3. Trabecular bone microarchitecture of azathioprine and vehicle treated mice treated with
3% DSS. (A) Representative 3D microCT reconstructions. Trabecular bone parameters between
treated and control groups, (B) bone volume/tissue volume (BV/TV), (C) trabecular number (Tb. N.),
(D) trabecular thickness (Tb. Th.), (E) trabecular separation (Tb. Sp.), (F) trabecular pattern factor
(Tb. Pf.), (G) trabecular bone mineral density (BMD). Data are presented as mean ± S.D. (n = 6/group).
* p < 0.05. ** p < 0.01.
2.4. Induction of Autophagy by Azathioprine in DSS Treated Mice
Histological analysis of the tibia sections appeared to confirm the results from the microCT
analysis, with an apparent reduction in bone volume (indicated by increased red osteoid staining) in the
trabecular bone in both the DSS treated mice (Figure 4Aii, in comparison to Figure 4Ai) and those treated
with azathioprine (Figure 4Aiii,iv, in comparison to Figure 4Ai). To examine whether azathioprine
affects autophagy activity in the skeleton of mice, immunohistochemistry for the autophagy marker
LC3 was conducted. LC3 labelling was observed in the osteoblasts lining the trabecular bone, in the
osteocytes and throughout the bone marrow. No differences were observed between non-DSS and DSS
treated mice (Figure 4Ci, in comparison to Figure 4Cii). However, azathioprine treatment appeared
to modestly increase the intensity of LC3 labelling, independent of DSS treatment and in particular
within the bone marrow, although no significant differences were observed upon quantification of
immunolabelling intensity (Figure 4Ciii,iv, in comparison with Figure 4Ci,ii, Figure S2).
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3. Discussion
Patients with IBD often present poor bone health and are 40% more at risk of bone fracture [3].
Azathioprine is widely used in the treatment of IBD and has been proven to be highly effective, however
it has previously been linked to an increase in fracture risk in humans [27]. Here we utilised the DSS
model of colitis in mice to delineate the effects of the azathioprine on the skeleton. Histopathological
analysis of the colon revealed successful induction of colitis in DSS treated mice, however, it also
revealed no differences in the severity or extent of inflammation in azathioprine treated mice compared
to vehicle-treated mice. This suggests that any noted effects of azathioprine on the skeleton may be
direct and not a consequence of altered nutrition through malabsorption of nutrients.
There are a number of risk factors associated with IBD-related bone loss including poor nutrient
intake/absorption, chronic inflammation, and use of glucocorticoids [5]. Central to the inflammatory
response is the chronic release of the pro-inflammatory cytokines IL-6 and TNF-α. Indeed IL-6 has been
identified as the predominant cytokine mediating the bone abnormalities, and genetic variations in IL-6
correlate well with the clinical course of IBD and the extent of bone loss [28,29]. These pro-inflammatory
cytokines are known to pro ote bone loss directly, but also through altered sensitivity and secretion
of growth hormone and insulin-like growth factor in IBD [30–32]. DSS-induced colitis is the result
of deterioration of the epithelial barrier, allowing for the influx of antigens and microorganisms,
and prompting the increased expression of these pro-inflammatory mediators [23,24]. Indeed this has
previously been shown to have detrimental effects on bone quality [25,26]. In accordance with these
studies, we observe worsened bone trabecular microarchitecture with DSS treatment in our mice.
Further, when azathioprine was administered alone it was also found to have a detrimental effect on
bone microarchitecture. This is consistent with previous reports of increased overall skeletal fracture
risk in individuals prescribed azathioprine [27], although it contra icts those in which combination
of anti-TNF-α and azathioprine had a positive effect [18]. The anti-TNF-α monoclonal antibody
infliximab has on its own been associated with increases in BMD and markers of bone which may
provide explanation as to the disparity between these results [15–17]. In addition, it has been suggested
that azathioprine can disrupt the bone remodelling process in a rat model by suppressing T lymphocytes
causing disturbances in the RANKL system responsible for osteoclast formation and activity [33].
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Specifically, the authors found that although the length and diameter of the bones remained unchanged,
azathioprine caused an overall reduction in femur and tibia mass, whilst also reducing the calcium
content. Further, the thickness of the trabeculae in the femur was found to be reduced in rats when
treated with azathioprine in both the distal epiphysis and metaphysis [33]. The bisphosphonate
alendronate prevented the development of these skeletal changes when administered in combination
with azathioprine [33]. These findings complement our findings here that the administration of
azathioprine may contribute to overall bone loss and trabecular bone deterioration. This suggests that
azathioprine alone may therefore not be a suitable drug of choice for IBD patients who are more at risk
of osteoporotic bone fractures, such as the elderly.
We hypothesised that the detrimental effects on bone caused by azathioprine may result in the
induction of the autophagy pathway, as azathioprine has already been shown to induce this process in
peripheral blood mononuclear cells and colorectal cancer cells [22,34]. Autophagy is a homeostatic
process in which cells degrade protein aggregates and damaged organelles [35]. Upon the induction of
autophagy, LC3-I becomes lipidated and becomes LC3-II before inserting into the autophagosome
membrane [36]. Because of this, the detection of LC3 within a sample is a recognised marker used
to show the presence of autophagy. Here we revealed increased LC3 labelling in our azathioprine
treated mice, suggestive of autophagy induction. This suggests that azathioprine is an effective
inducer of autophagy activity in the skeleton. The reasons for this are currently speculative, as it is
currently not known whether autophagy is indirectly induced as a survival mechanism to cope with
the adverse effects caused by azathioprine on bone health. Similarly, the precise effects of azathioprine
on osteoblast function are currently unknown. The effects of another autophagy inducer, rapamycin,
are well documented however, albeit through somewhat controversial findings. It has been shown that
rapamycin, in the presence of lipopolysaccharides, can promote the differentiation of human embryonic
stem cells (hESCs) into mature osteoblasts by modulating mTOR signalling [37,38]. However, it was
also found that rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells. It was
observed that even at low concentrations (0.1–20 nM), rapamycin reduced osteocalcin and osterix
mRNA expression in differentiating MC3T3-E1 osteoblasts, as well as reducing their mineralisation
capacity [39]. Therefore, this further highlights the need to understand more fully the mechanism of
action of azathioprine before a better level of care for patients can be provided.
In conclusion, the data in this manuscript suggest that azathioprine treatment may have a
deleterious effect on bone health in IBD patients who may already be at increased risk of osteoporotic
bone fractures, and thus will inform on future treatment strategies for patient stratification.
4. Materials and Methods
4.1. Animals
Male 10-week old C57BL/6J mice (n = 6/group) (Charles River, UK) were treated with 3% DSS
(molecular mass ~40,000 kD; MP Biomedical, Eschwege, Germany) in their drinking water ad libitum
for 4 days, following which they were given normal tap water for a 14-day recovery period. Control
(non-DSS treated) male mice received normal tap water for the duration of the study. The dose and
duration of the DSS treatment was based on previous studies using the same mouse strain, age,
and sex [26]. It is important to note that this model is unable to distinguish between ulcerative colitis
and Crohn’s disease. Mice were treated using an oral gavage daily throughout the experiment with
10 mg/kg/day of azathioprine or a vehicle control (n = 6/group). The health status of the DSS-treated
mice was scored daily, with particular attention paid to their coat condition, mobility, presence of
blood in stools, and eye clarity. The body weights of all mice were recorded daily. After the 14-day
recovery period, the mice were culled and blood, colon, and bone samples collected. Mice were
kept in polypropylene cages, with light/dark 12 h cycles, at 21 ± 2 ◦C, and fed ad libitum with a
maintenance diet (Special Diet Services, Witham, UK). All experimental protocols were approved by
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Roslin Institute’s Animal Users Committee (A911; 3/10/2017) and the animals were maintained in
accordance with UK Home Office guidelines for the care and use of laboratory animals.
4.2. Colon Pathology
The colon was dissected from all mice, measured and fixed in 4% paraformaldehyde (PFA) for 24 h.
Each colon was divided into 3 transverse segments including proximal, middle, and distal portions.
Tissue processing, wax embedding, sectioning (5 µm thick) and Hematoxylin and eosin (H&E) staining
were conducted following routine procedures. Colon pathology was graded blind on sections from all
3 segments of each mouse using an established histological grading scheme (Table S2) [40,41]. Scores
from all three segments were averaged to provide an overall pathology score, as well being analysed in
the separate regions of the colon.
4.3. Bone Histology and Immunohistochemistry
The tibia was dissected from all mice, fixed in 4% formaldehyde, and decalcified in 10%
ethylenediaminetetraacetic acid (EDTA) at 4 ◦C. Tissue processing, wax embedding, and sectioning
(5 µm thick) were done following routine procedures. Tibia sections were stained for histological
analysis using the Goldner’s stain, and H&E following standard protocols. For immunohistochemistry,
sections were dewaxed in xylene, rehydrated in graded alcohol, and incubated for 90 min at 70 ◦C
in 10 mM citrate buffer for antigen retrieval. Any endogenous peroxidase activity was blocked by
using 0.3% H2O2 for 30 min at room temperature. LC3 (1:500, polyclonal raised in rabbit; MBL Bio)
antibodies were used with an appropriate IgG control (Suppl. Figure 2). The Vectastain ABC universal
kit (Vector Laboratories, Peterborough, UK) was used according to the manufacturer’s instructions.
The samples were counterstained with haematoxylin before being dehydrated and mounted using
DePex. Quantification of immunolabelling was conducted using reciprocal intensity and the open
source software Image J (http://fiji.sc/) [42].
4.4. MicroCT
To evaluate trabecular microarchitecture and cortical bone geometry of the tibia from control and
DSS-treated mice, we used microCT (Skyscan 1172 X-ray microtomograph, Bruker, Kontich, Belgium)
as described previously [43]. In brief, high-resolution scans with an isotropic voxel size of 5 µm were
acquired (60 kV, 0.5 mm aluminium filter, 0.6◦ rotation angle). Two images were averaged at each
rotation angle. Scan reconstruction was conducted using NRecon software (Bruker) and each bone
was analysed using CtAN (Bruker). For the trabecular analysis, the base of the growth plate was used
as a standard reference point. A 1.25 mm trabecular bone region, located at 5% of the total length
beneath this reference point, was analysed. To investigate the changes in the cortical bone geometry,
two 0.5 mm sections were analysed at 37% and 50% of the total bone length from the reference starting
slice (first appearance of the medial tibial condyles). To assess BMD, phantoms were used to calibrate
the CTAn software. BMD phantoms of known calcium hydroxyapatite mineral densities of 0.25 and
0.75 g/cm3 were scanned and reconstructed using the same parameters as used for bone samples.
4.5. Statistical Analysis
Data are expressed as the mean ± standard deviation (S.D.). A power analysis was conducted
on microCT data from a previous study using an identical model and 6 experimental mice per group
were required to detect statistically significant differences in the bone trabecular microarchitecture [26].
Analysis was performed by one-way analysis of variance (ANOVA) with appropriate post-hoc tests.
p < 0.05 was considered to be significant and noted as *, with p values of < 0.01 and < 0.001 were noted
as ** and *** respectively.
Int. J. Mol. Sci. 2019, 20, 6085 9 of 11
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/23/
6085/s1.
Author Contributions: Conceptualization, K.A.S., C.S.; formal analysis, S.M., K.M.H., E.M.M., K.A.S., C.S.; data
curation, S.M., K.M.H., E.M.M.; methodology, K.A.S., C.S., C.F.; writing—original draft preparation, S.M., K.A.S.,
C.S.; writing—review and editing, S.M., K.M.H., E.M.M., C.F., C.S., K.A.S.; supervision, K.A.S., C.S.; project
administration, K.A.S.; funding acquisition, K.A.S., C.S.
Funding: This research was funded by an Edinburgh Napier University School of Applied Sciences Research
Excellence Grant (to K.A.S. and C.S.), and an Edinburgh Napier University Vice Chancellor’s Fellowship (to K.A.S.).
We are also grateful to the Biotechnology and Biological Sciences Research Council (BBSRC) for Institute Strategic
Programme Grant Funding to C.F. (BB/J004316/1).
Acknowledgments: We are extremely thankful to the BRF staff at the Roslin Institute, especially Izabela Sabok.
Images for the graphical abstract were from Servier Medical Art.
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Zhang, Y.-Z.; Li, Y.-Y. Inflammatory bowel disease: Pathogenesis. World J. Gastroenterol. 2014, 20, 91–99.
[CrossRef] [PubMed]
2. England, N. Nhs Standard Contract for Colorectal: Complex Inflammatory Bowel Disease (Adult). NHS Engl.
2013, 14, 1–6.
3. Ali, T.; Lam, D.; Bronze, M.S.; Humphrey, M.B. Osteoporosis in Inflammatory Bowel Disease. Am. J. Med.
2009, 122, 599–604. [CrossRef] [PubMed]
4. Bianchi, M.L. Inflammatory bowel diseases, celiac disease, and bone. Arch. Biochem. Biophys. 2010, 503,
54–65. [CrossRef]
5. Lima, C.A. Risk factors for osteoporosis in inflammatory bowel disease patients. World J. Gastrointest.
Pathophysiol. 2015, 6, 210. [CrossRef]
6. Blanck, S.; Aberra, F. Vitamin D deficiency is associated with ulcerative colitis disease activity. Dig. Dis. Sci.
2013, 58, 1698–1702. [CrossRef]
7. Jørgensen, S.P.; Hvas, C.L.; Agnholt, J.; Christensen, L.A.; Heickendorff, L.; Dahlerup, J.F. Active Crohn’s
disease is associated with low vitamin D levels. J. Crohns Colitis 2013, 7, e407–e413. [CrossRef]
8. Silvennoinen, J.; Lamberg-Allardt, C.; Kärkkäinen, M.; Niemelä, S.; Lehtola, J. Dietary calcium intake and
its relation to bone mineral density in patients with inflammatory bowel disease. J. Intern. Med. 1996, 240,
285–292. [CrossRef]
9. Moschen, A.R.; Kaser, A.; Enrich, B.; Ludwiczek, O.; Gabriel, M.; Obrist, P.; Wolf, A.M.; Tilg, H.
The RANKL/OPG system is activated in inflammatory bowel diseases and relates to the state or bone
loss. Gut 2005, 54, 479–487. [CrossRef]
10. Bernstein, C.N.; Sargent, M.; Leslie, W.D. Serum osteoprotegerin is increased in Crohn’s disease:
A population-based case control study. Inflamm. Bowel Dis. 2005, 11, 325–330. [CrossRef]
11. Turk, N.; Cukovic-Cavka, S.; Korsic, M.; Turk, Z.; Vucelic, B. Proinflammatory cytokines and receptor
activator of nuclear factor κB-ligand/osteoprotegerin associated with bone deterioration in patients with
Crohn’s disease. Eur. J. Gastroenterol. Hepatol. 2009, 21, 159–166. [CrossRef] [PubMed]
12. Lee, N.; Radford-Smith, G.L.; Forwood, M.; Wong, J.; Taaffe, D.R. Body composition and muscle strength as
predictors of bone mineral density in Crohn’s disease. J. Bone Miner. Metab. 2009, 27, 456–463. [CrossRef]
[PubMed]
13. Abraham, B.P.; Prasad, P.; Malaty, H.M. Vitamin D deficiency and corticosteroid use are risk factors for low
bone mineral density in inflammatory bowel disease patients. Dig. Dis. Sci. 2014, 59, 1878–1884. [CrossRef]
[PubMed]
14. Lane, N.E. Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments.
Curr. Osteoporos. Rep. 2019, 17, 1–7. [CrossRef]
15. Miheller, P.; Muzes, G.; Rácz, K.; Blázovits, A.; Lakatos, P.; Herszényi, L.; Tulassay, Z. Changes of OPG and
RANKL concentrations in Crohn’s disease after infliximab therapy. Inflamm. Bowel Dis. 2007, 13, 1379–1384.
[CrossRef]
Int. J. Mol. Sci. 2019, 20, 6085 10 of 11
16. Franchimont, N.; Putzeys, V.; Collette, J.; Vermeire, S.; Rutgeerts, P.; De Vos, M.; Van Gossum, A.;
Franchimont, D.; Fiasse, R.; Pelckmansj, P.; et al. Rapid improvement of bone metabolism after infliximab
treatment in Crohn’s disease. Aliment. Pharmacol. Ther. 2004, 20, 607–614. [CrossRef]
17. Abreu, M.T.; Geller, J.L.; Vasiliauskas, E.A.; Kam, L.Y.; Vora, P.; Martyak, L.A.; Yang, H.; Hu, B.; Lin, Y.C.;
Keenan, G.; et al. Treatment with infliximab is associated with increased markers of bone formation in
patients with Crohn’s disease. J. Clin. Gastroenterol. 2006, 40, 55–63. [CrossRef]
18. Krajcovicova, A.; Hlavaty, T.; Killinger, Z.; Miznerova, E.; Toth, J.; Letkovsky, J.; Nevidanska, M.; Cierny, D.;
Koller, T.; Zelinkova, Z.; et al. Combination therapy with an immunomodulator and anti-TNFα agent
improves bone mineral density in IBD patients. J. Crohns Colitis 2014, 8, 1693–1701. [CrossRef]
19. Denson, L.A. The role of the innate and adaptive immune system in pediatric inflammatory bowel disease.
Inflamm. Bowel Dis. 2013, 19, 2011–2020. [CrossRef]
20. Hooper, K.M.; Barlow, P.G.; Stevens, C.; Henderson, P. Inflammatory bowel disease drugs: A focus on
autophagy. J. Crohns Colitis 2017, 11, 118–127. [CrossRef]
21. Yu, L.; Chen, Y.; Tooze, S.A. Autophagy pathway: Cellular and molecular mechanisms. Autophagy 2018, 14,
207–215. [CrossRef] [PubMed]
22. Hooper, K.M.; Casanova, V.; Kemp, S.; Staines, K.A.; Satsangi, J.; Barlow, P.G.; Henderson, P.; Stevens, C.
The Inflammatory Bowel Disease Drug Azathioprine Induces Autophagy via mTORC1 and the Unfolded
Protein Response Sensor PERK. Inflamm. Bowel Dis. 2019, 25, 1481–1496. [CrossRef] [PubMed]
23. Perše, M.; Cerar, A. Dextran sodium sulphate colitis mouse model: Traps and tricks. J. Biomed. Biotechnol.
2012, 2012, 718617. [CrossRef] [PubMed]
24. Araki, Y.; Mukaisyo, K.I.; Sugihara, H.; Fujiyama, Y.; Hattori, T. Increased apoptosis and decreased
proliferation of colonic epithelium in dextran sulfate sodium-induced colitis in mice. Oncol. Rep. 2010, 24,
869–874. [CrossRef]
25. Hamdani, G.; Gabet, Y.; Rachmilewitz, D.; Karmeli, F.; Bab, I.; Dresner-Pollak, R. Dextran sodium
sulfate-induced colitis causes rapid bone loss in mice. Bone 2008, 43, 945–950. [CrossRef]
26. Dobie, R.; MacRae, V.E.; Pass, C.; Milne, E.M.; Ahmed, S.F.; Farquharson, C. Suppressor of cytokine signaling
2 (Socs2) deletion protects bone health of mice with DSS-induced inflammatory bowel disease. Dis. Model.
Mech. 2018, 11, dmm028456. [CrossRef]
27. Vestergaard, P.; Rejnmark, L.; Mosekilde, L. Methotrexate, azathioprine, cyclosporine, and risk of fracture.
Calcif. Tissue Int. 2006, 79, 69–75. [CrossRef]
28. Schulte, C.M.S.; Dignass, A.U.; Goebell, H.; Roher, H.D.; Schulte, K.M. Genetic factors determine extent of
bone loss in inflammatory bowel disease. Gastroenterology 2000, 119, 909–920. [CrossRef]
29. Paganelli, M.; Albanese, C.; Borrelli, O.; Civitelli, F.; Canitano, N.; Viola, F.; Passariello, R.; Cucchiara, S.
Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease.
Inflamm. Bowel Dis. 2007, 13, 416–423. [CrossRef]
30. Fernandez-Vojvodich, P.; Zaman, F.; Sävendahl, L. Interleukin-6 acts locally on the growth plate to impair
bone growth. Ann. Rheum. Dis. 2013, 72, e24. [CrossRef]
31. Wong, S.; Smyth, A.; McNeill, E.; Galloway, P.; Hassan, K.; McGrogan, P.; Ahmed, S. The growth hormone
insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth
retardation. Clin. Endocrinol. 2010, 73, 220–228.
32. Wong, S.C.; Dobie, R.; Altowati, M.A.; Werther, G.A.; Farquharson, C.; Ahmed, S.F. Growth and the growth
hormone-insulin like growth factor 1 axis in children with chronic inflammation: Current Evidence, Gaps in
Knowledge, and Future Directions. Endocr. Rev. 2016, 37, 62–110. [CrossRef] [PubMed]
33. Cegiela, U.; Kaczmarczyk-Sedlak, I.; Pytlik, M.; Folwarczna, J.; Nowin´ska, B.; Fronczek-Sokół, J. Alendronate
prevents development of the skeletal changes induced by azathioprine in rats. Acta Pol. Pharm. Drug Res.
2013, 70, 309–315.
34. Chaabane, W.; Appell, M.L. Interconnections between apoptotic and autophagic pathways during
thiopurine-induced toxicity in cancer cells: The role of reactive oxygen species. Oncotarget 2016, 7,
75616–75634. [CrossRef]
35. Henderson, P.; Stevens, C. The Role of Autophagy in Crohn’s Disease. Cells 2012, 1, 492–519. [CrossRef]
36. Nollet, M.; Santucci-Darmanin, S.; Breuil, V.; Al-Sahlanee, R.; Cros, C.; Topi, M.; Momier, D.; Samson, M.;
Pagnotta, S.; Cailleteau, L.; et al. Autophagy in osteoblasts is involved in mineralization and bone homeostasis.
Autophagy 2014, 10, 1965–1977. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 6085 11 of 11
37. Lee, K.-W.; Yook, J.-Y.; Son, M.-Y.; Kim, M.-J.; Koo, D.-B.; Han, Y.-M.; Cho, Y.S. Rapamycin promotes the
osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating
the BMP/Smad pathway. Stem Cells Dev. 2010, 19, 557–568. [CrossRef]
38. Li, X.; Chang, B.; Wang, B.; Bu, W.; Zhao, L.; Liu, J.; Meng, L.; Wang, L.; Xin, Y.; Wang, D.; et al. Rapamycin
promotes osteogenesis under inflammatory conditions. Mol. Med. Rep. 2017, 16, 8923–8929. [CrossRef]
39. Singha, U.K.; Jiang, Y.; Yu, S.; Luo, M.; Lu, Y.; Zhang, J.; Xiao, G. Rapamycin inhibits osteoblast proliferation
and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J. Cell. Biochem. 2008,
103, 434–446. [CrossRef]
40. Williams, K.L.; Fuller, C.R.; Dieleman, L.A.; DaCosta, C.M.; Haldeman, K.M.; Sartor, R.B.; Lund, P.K.
Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that
overexpress growth hormone. Gastroenterology 2001, 120, 925–937. [CrossRef]
41. Dieleman, L.A.; Palmen, M.J.H.J.; Akol, H.; Bloemena, E.; Peña, A.S.; Meuwissen, S.G.M.; Van Rees, E.P.
Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2
cytokines. Clin. Exp. Immunol. 1998, 114, 385–391. [CrossRef] [PubMed]
42. Nguyen, D.H.; Zhou, T.; Shu, J.; Mao, J.-H. Quantifying Chromogen Intensity in Immunohistochemistry via
Reciprocal Intensity. Available online: www.CancerInCytes.org (accessed on 19 November 2019).
43. Staines, K.A.; Javaheri, B.; Hohenstein, P.; Fleming, R.; Ikpegbu, E.; Unger, E.; Hopkinson, M.; Buttle, D.J.;
Pitsillides, A.A.; Farquharson, C. Hypomorphic conditional deletion of E11/Podoplanin reveals a role in
osteocyte dendrite elongation. J. Cell. Physiol. 2017. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
